IRS2 and chronic myelogenous leukemia, BCR-ABL1 positive: Likewise, the IRS-2 overexpression is observed in patients with non-CML chronic myeloproliferative disorders; the silencing of IRS-2 reduced cell viability and increased apoptosis in cells harboring the pathogenetic JAK2V617F mutation and enhanced the effects of JAK1/2 inhibitor ruxolitinib [122].